Initiate first patient dosing in the Phase 2 combination study in NSCLC
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 5 Jan 2021
- Due
- 31 Dec 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“First patient dosing planned for 2H 2021”
What we found
Evidence strength A What the grades mean
The company planned to initiate the Phase 2 NSCLC study in 2H 2021, but filings confirm the trial was initiated in the second quarter of 2022.
-
A Galecto, Inc. 10-Q filed 2022-07-29
“We initiated the GALLANT-1 trial in the second quarter of 2022” ✓ confirmed on the page
-
A Galecto, Inc. 8-K filed 2022-01-05
“GB1211 – Phase 2a study in NSCLC in combination with checkpoint inhibitor (planned initiation in 1H 2022 and top-line data expected in mid-2023)” ✓ confirmed on the page
Market reaction: the shares moved -8.9% against the S&P 500 over the three sessions around the disclosure (4 Jan 2022 to 7 Jan 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- First patient dosing in Phase 2 combination study in NSCLC
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Galecto, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-DMRA-021088 · Corrections policy